Positive Trial Results For Arena Pharmaceuticals


Arena Pharmaceuticals Inc. (Nasdaq: ARNA) reported positive results from a late stage clinical trial of its obesity treatment lorcaserin sending the stock price soaring $1.00 to close at $4.94.

About this Entry

This page contains a single entry by published on June 8, 2009 1:59 PM.

Ireland's Credit Rating Downgraded was the previous entry in this blog.

FDA Approves MDRNA's Generic Osteoporosis Nasal Spray is the next entry in this blog.

Find recent content on the main index or look in the archives to find all content.

Powered by Movable Type 5.12